Cerdelga (eliglustat) — Highmark
Gaucher disease type 1
Reauthorization criteria
- Member has experienced positive clinical response to therapy demonstrated by one or more of the following: reduction in liver volume, reduction in spleen volume, increase in hemoglobin levels, or increase in platelet counts
- An appropriate quantity is being utilized based on CYP2D6 metabolizer status (extensive metabolizer or intermediate metabolizer; not a CYP2D6 ultra-rapid metabolizer)
Approval duration
12 months